“This is the way this deal works: Heads, Fife wins and we all win with him. Tails, Fife wins, we get diluted to smitherines, and he tries to figure out what to do with Leronlimab.”

IMO, NP should’ve completed public offering of stock in the $4-7 range and netted $100 million or so. Yes, that would’ve diluted stock holders, but if you read the quarterly and yearly reports, CYDY is paying a good portion of the interest of the Fife notes with shares, not cash. So either way shares are diluted, but the Fife deals are costing much more.